Aligos Q4 2021 net loss $37.7M; cash $205.8M; pipeline advances with 3 candidates in clinic

Aligos Therapeutics, Inc.

Net loss Q4 2021 $37.7M ($0.89/share) vs $34.4M in Q4 2020; full year loss $128.3M ($3.22/share).
Cash and investments $205.8M at Dec 31, 2021; sufficient to fund operations into first half 2024.
CAM (ALG-000184) shows best-in-class HBV DNA/RNA reductions; 12-week studies planned for H2 2022.
ASO (ALG-020572) Phase 1b in CHB initiated, first cohort enrolled; data expected at a conference in H2 2022.
Expanded Merck NASH collaboration for second oligonucleotide target; COVID-19 3CL PI candidates more potent than nirmatrelvir.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.